Corvidia Therapeutics

The years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial

When Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi

Novo Nordisk A/S has opened its bulging wallet to acquire Germany's Cardior Pharmaceuticals GmbH , boosting its cardiovascular pipeline through a deal worth up to €1.03bn. The Hannover-based biotech

With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimat